Excited to be the first patient in a novel clinical trial, Jon Woods is hoping that an infusion of immune natural killer cells donated by his son will beat back the metastatic cancer he has battled for four years. “I’m upbeat [and] I’m happy to be a pioneer,” says Woods, 65, a retired postal worker … Continued
In their quest for effective targeted therapies to treat triple-negative breast cancer (TNBC) — an aggressive disease that often doesn’t respond to standard chemotherapy — researchers at Dana-Farber and elsewhere have recently focused on the potential of drugs known as BET bromodomain inhibitors. BET inhibitors target a family of proteins including BRD2, BRD3, BRD4, and … Continued
Ependymomas are some of the most difficult-to-treat brain tumors. Mariella Filbin, MD, PhD, a neuro-oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is driven by a desire to find new therapies for these pediatric brain tumors. At the core of her work is an effort to uncover the events that shape tumor development. Defining how … Continued
Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Continued
Liver cancer that develops in people with obesity and Type 2 diabetes is dependent on elevated amounts of a protein that might be targeted for treatment by two existing drugs, say Dana-Farber scientists. The research reported in Cancer Research by Pere Puigserver, PhD, and colleagues pertains specifically to liver cancer in individuals who are obese … Continued
For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results … Continued
Insights from decades of cancer research are surprisingly transferable to the battle against COVID-19. The desire to save life and ease suffering that motivates cancer researchers has been directed to the new disease as well. Drawing on their knowledge of cancer drug mechanisms, and of the adverse side effects of some of those drugs, Dana-Farber … Continued
Human cells in distress — either because they’re infected by a virus or have become cancerous — have a formidable army of defenders at their disposal: white blood cells and other agents of the immune system that can come to the rescue. Bacterial cells aren’t as fortunate. Living in colonies of their own kind, they … Continued
Dana-Farber researchers, with colleagues at Columbia University and the National Institutes of Health, have identified a diverse set of antibodies that effectively neutralize the coronavirus responsible for COVID-19, a key step in the development of agents to treat and prevent the disease. As reported in Nature, the antibodies exhibited “exquisite potency” against the virus, thwarting … Continued
The intriguing case of a man with melanoma tumors that responded in different ways to the same checkpoint-blocking drug has yielded an important clue to the causes of resistance to immunotherapy treatments, according to Dana-Farber researchers. The findings could help guide the use of immunotherapy in individual patients. The 74-year-old patient, described in a report … Continued
As a tool for editing cell DNA, the protein Cas9 is prized for its precision, its ability to snip DNA at specific locations without producing repercussions elsewhere in the genome. On the basis of a recent study by Dana-Farber scientists, that reputation for unobtrusiveness will have to be revised. In a paper in Nature Genetics, … Continued
By Wayne Marasco, MD, PhD, Professor in the Dana-Farber Department of Cancer Immunology and Virology and Professor of Medicine at Harvard Medical School Many millions of people around the globe have had COVID-19. The vast majority of people have recovered, but several hundreds of thousands of people have died from the virus. This pandemic has had … Continued
By Wayne Marasco, MD, PhD, Professor in the Dana-Farber Department of Cancer Immunology and Virology and Professor of Medicine at Harvard Medical School There is great hope surrounding the release of COVID-19 antibody tests, which could determine whether a person has developed immunity to the virus. We would all benefit if the test results could … Continued
The resilience shown by cancer care providers during the coronavirus crisis is in equal supply among those involved in clinical research. The strict protocols associated with these studies — rules on eligibility, consent, criteria for tracking response, data collection and analysis — might seem to allow little of the flexibility needed in the COVID-19 era. … Continued
Five years into his treatment for multiple myeloma, Mark Young was attending a Dana-Farber conference to learn about the latest research in the disease when his oncologist — Paul Richardson, MD, clinical program leader and director of clinical research at the Institute’s Jerome Lipper Multiple Myeloma Center — came running up with some timely news. … Continued
As scientists race to develop and test new treatments for COVID-19, Dana-Farber’s Wayne Marasco, MD, PhD, and his lab team are bringing one of the world’s most formidable resources to the effort: a “library” of 27 billion human antibodies against viruses, bacteria, and other bodily invaders. The collection, created by Marasco and his associates in … Continued
A massive international effort has taken a big step toward mapping all the major cancer-causing mutations in the human genome, generating new knowledge about how tumors form. The extensive role played by large-scale structural mutations in cancer was among the findings of the Pan-Cancer Analysis of Whole Genomes (PCAWG) Project, according to Rameen Beroukhim, MD, … Continued
This article was written by Donna Vatnick, BS, clinical research coordinator in Dana-Farber Cancer Institute’s Center for Cancer Genetics and Prevention. Historically, cancer risk has been confined to the binary: male versus female. After the discovery of BRCA1 and BRCA2 in the mid-90s, testing of these genes was most often recommended to women. The substantially … Continued
Immunotherapy for cancer has made some of its biggest inroads against hematologic malignancies such as leukemia and lymphoma, with treatments such as checkpoint inhibitors and CAR T-cell therapies producing long-lasting remissions in some patients. But there’s broad agreement that the potential of such therapies has only begun to be tapped and that combining immunotherapy drugs … Continued
